Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer
Ivanova T et al. – Bone morphogenetic protein 4 (BMP4) epigenetic and expression status may represent promising biomarkers for gastric cancer (GC) cisplatin resistance. Targeting BMP4 may sensitise GC cells to cisplatin. Oxaliplatin, a clinically acceptable cisplatin alternative, may represent a potential therapeutic option for BMP4–positive GCs.